🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our VP, Translational Biology Andrew Pierce will be presenting at Cambridge NTF’s event ‘Exploring immunology disease processes, disease segmentation and immune therapeutics’, hosted by AstraZeneca, taking place on 4 Dec in Cambridge. You can sign up here: eventbrite.com/e/cambridge-ne…

We are pleased to announce that the first patients in the US have been dosed in our ongoing Phase 1b study of CB307, Crescendo’s lead programme in PSMA+ metastatic castration-resistant prostate cancer (mCRPC). Read the press release here: crescendobiologics.com/press-release/ Fred Hutch Cancer Center

2023 has been an exciting and rewarding year for all of us here at Crescendo Biologics, bringing continued progress in the development of our lead asset CB307, a first-in-class programme for treating PSMA+ mCRPC. We look forward to another exciting year in 2024. #HappyNewYear

Our CEO Theo Harold, CDO Dr Philip Bland-Ward, CMO Dr Kenji Hashimoto, and VP, Translational Biology Dr Andrew Pierce will be attending the @JPMorgan Healthcare Conference 2024 taking place in SF, CA from 8-11 Jan. We look forward to insightful discussions. #JPMHC24

Our CMO Dr Kenji Hashimoto is looking forward to discussing the latest advancements in prostate cancer therapy and making new connections at the ASCO #GU24 Cancers Symposium this week (25-27 Jan) #ProstateCancer #Immunotherapy

We are delighted to have been included in Labiotech.eu’s overview of innovative UK #biotech companies. Read @willowshahnev’s full article here: labiotech.eu/best-biotech/u… #immunotherapy #immunooncology

Peer-reviewed journal Neoplasia has published a paper which details positive preclinical data for Crescendo’s half-life extended CD137 x PSMA, demonstrating superior tumour penetration. Collaboration with Michigan Chemical Engineering PR: crescendobiologics.com/press-release/ Paper: sciencedirect.com/science/articl…

Our Chief Medical Officer, Kenji Hashimoto, joins the conversation in Scrip, Citeline Commercial's latest #ScripAsks, about the therapeutic advances expected in 2024. To read the full article, please visit: scrip.citeline.com/SC149780/Scrip… #mCRPC #Cancer #Biotech #Therapeutics

Our CEO Theo Harold and CDO Phil Bland-Ward are attending TDCowen’s Health Care Conference from 4-6 March in Boston. To arrange a meeting with the team, contact: [email protected] #TDCowenHealthCare #Therapeutics

The Crescendo team will be presenting two posters at the 2024 AACR Annual Meeting, during the Immune Modulation Employing Agonist or Co-Stimulatory Approaches Session on Tuesday 9 April 2024. Read further details here: crescendobiologics.com/press-release/

We are pleased to be attending #BIOEuropeSpring 2024 in Barcelona. If you would like to meet us to discuss our Humabody® platform or T cell enhancing pipeline, please reach out to us via the partnering platform - we look forward to speaking with you. #biopharma #immunooncology

We are delighted to have been named a finalist for 'Biotech of the Year', and for our CEO, Theo Harold, to have been nominated for 'CEO of the Year' at this year's Cambridge Independent #SciTechAwards

Join our team as we present two posters at the 2024 AACR Annual Meeting Immune Modulation Employing Agonist or Co-Stimulatory Approaches Session on Tues 9 April. To learn more: crescendobiologics.com/press-release/

We are thrilled to be publishing preclinical data for our lead programme, CB307, in Clinical Cancer Research, including our collaborative work with The ICR. (crescendobiologics.com/wp-content/upl…)

Last night, Crescendo attended the Cambridge Independent #Science and #Technology Awards. It is truly an honour to be a part of the #Cambridge scientific ecosystem. Thanks also to the sponsor of the ‘Biotech of the Year’ category Chesterford Research Park

Our CMO Kenji Hashimoto & CDO Philip Bland-Ward will be attending ASCO from 31 May – 4 June in Chicago & look forward to connecting with #oncology professionals & hearing the latest innovations in #cancer. To arrange a meeting, contact: [email protected]

Our Associate Director, BD Dr Amanda You will attend the #BIO2024 International Convention in San Diego. If you would like to meet her, please reach out on the partnering platform.

We are excited to announce that our partner Zai Lab has dosed its first patient in a global Phase 2 clinical trial evaluating the efficacy and safety of the IL-17 targeted Humabody® VH ZL-1102, for the topical treatment of chronic plaque psoriasis. crescendobiologics.com/wp-content/upl…

Our scientists along with Professor Greg Thurber’s laboratory at Michigan Chemical Engineering have co-written a paper recently published in The AAPS Journal, on the functional design of immune cell targeting therapeutics. link.springer.com/article/10.120… #Biotech #Therapeutics #Discovery

Crescendo scientists and Resolian, have co-authored a paper in Bioanalysis Journal. The paper outlines a method to quantify CB307 (bispecific Humabody® VH) in blood, which is being used to support our ongoing Phase 1b POTENTIA trial. tandfonline.com/doi/full/10.10…